RS53761B1 - Farmaceutski preparati sa (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom insulina - Google Patents

Farmaceutski preparati sa (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom insulina

Info

Publication number
RS53761B1
RS53761B1 RS20150042A RSP20150042A RS53761B1 RS 53761 B1 RS53761 B1 RS 53761B1 RS 20150042 A RS20150042 A RS 20150042A RS P20150042 A RSP20150042 A RS P20150042A RS 53761 B1 RS53761 B1 RS 53761B1
Authority
RS
Serbia
Prior art keywords
combination
compound
insulin secretagogue
glimepiride
diabetes mellitus
Prior art date
Application number
RS20150042A
Other languages
English (en)
Serbian (sr)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co. Ltd. filed Critical Taisho Pharmaceutical Co. Ltd.
Publication of RS53761B1 publication Critical patent/RS53761B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20150042A 2009-04-16 2010-04-16 Farmaceutski preparati sa (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom insulina RS53761B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16

Publications (1)

Publication Number Publication Date
RS53761B1 true RS53761B1 (sr) 2015-06-30

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20150042A RS53761B1 (sr) 2009-04-16 2010-04-16 Farmaceutski preparati sa (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom insulina
RS20130508A RS53056B (sr) 2009-04-16 2010-04-16 Farmaceutski preparat koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin i njegove upotrebe u lečenju dijabetesa

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20130508A RS53056B (sr) 2009-04-16 2010-04-16 Farmaceutski preparat koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin i njegove upotrebe u lečenju dijabetesa

Country Status (30)

Country Link
US (1) US20120040898A1 (OSRAM)
EP (3) EP2829271A3 (OSRAM)
JP (4) JP5077786B2 (OSRAM)
KR (2) KR20120016051A (OSRAM)
CN (7) CN105477639A (OSRAM)
AR (1) AR076317A1 (OSRAM)
AU (1) AU2010237748B2 (OSRAM)
BR (1) BRPI1012539A2 (OSRAM)
CA (1) CA2755392A1 (OSRAM)
CY (2) CY1114703T1 (OSRAM)
DK (2) DK2419097T3 (OSRAM)
ES (2) ES2431300T3 (OSRAM)
HK (6) HK1217302A1 (OSRAM)
HR (2) HRP20131120T1 (OSRAM)
ME (2) ME01555B (OSRAM)
MX (1) MX2011010901A (OSRAM)
MY (3) MY183793A (OSRAM)
NZ (4) NZ595314A (OSRAM)
PH (3) PH12015500235A1 (OSRAM)
PL (2) PL2601949T3 (OSRAM)
PT (2) PT2601949E (OSRAM)
RS (2) RS53761B1 (OSRAM)
RU (2) RU2532330C2 (OSRAM)
SG (6) SG2014012405A (OSRAM)
SI (2) SI2601949T1 (OSRAM)
SM (1) SMT201500015B (OSRAM)
TW (3) TW201622720A (OSRAM)
UA (2) UA105216C2 (OSRAM)
WO (1) WO2010119990A1 (OSRAM)
ZA (1) ZA201106727B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2849776B1 (en) 2012-05-17 2021-04-21 vTv Therapeutics LLC Glucokinase activator compositions for the treatment of diabetes
KR20150046125A (ko) * 2012-08-30 2015-04-29 다이쇼 세이야꾸 가부시끼가이샤 Sglt2 저해약과 항고혈압약의 조합
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
KR102060728B1 (ko) * 2015-02-27 2019-12-30 재단법인 아산사회복지재단 Dpp-4 억제제를 포함하는 판막 석회화의 예방 또는 치료용 조성물
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
KR20190070956A (ko) 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations
CN110168098A (zh) * 2016-11-14 2019-08-23 高雄医学大学 一种检测糖代谢异常的方法及其预防及治疗
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
EP4487909A3 (en) 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
PE20211467A1 (es) 2018-10-29 2021-08-05 Boehringer Ingelheim Int Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
JP2004536047A (ja) * 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
BRPI0713058A2 (pt) * 2006-06-29 2012-04-10 Taisho Pharmaceutical Co., Ltd. composto de 1-tioglucitol de c-fenila
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008055940A2 (en) * 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv

Also Published As

Publication number Publication date
PH12019500961A1 (en) 2020-08-03
PH12019500959A1 (en) 2020-06-29
EP2419097A1 (en) 2012-02-22
NZ710575A (en) 2016-06-24
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
DK2419097T3 (da) 2013-10-28
HRP20131120T1 (hr) 2013-12-20
PL2601949T3 (pl) 2015-04-30
CY1114703T1 (el) 2016-10-05
UA105216C2 (en) 2014-04-25
HK1217301A1 (zh) 2017-01-06
JP2016104775A (ja) 2016-06-09
SG2014012462A (en) 2014-05-29
SG2014012553A (en) 2014-05-29
HK1217434A1 (zh) 2017-01-13
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
ME02015B (me) 2015-05-20
EP2601949A2 (en) 2013-06-12
JP5660094B2 (ja) 2015-01-28
ES2523408T3 (es) 2014-11-25
MY182720A (en) 2021-02-03
HK1218881A1 (zh) 2017-03-17
SG2014014807A (en) 2014-05-29
PH12015500235B1 (en) 2015-12-02
RS53056B (sr) 2014-04-30
TW201103534A (en) 2011-02-01
MY156679A (en) 2016-03-15
AU2010237748B2 (en) 2014-10-30
AR076317A1 (es) 2011-06-01
WO2010119990A1 (en) 2010-10-21
NZ623838A (en) 2015-09-25
RU2011146335A (ru) 2013-05-27
ME01555B (me) 2014-04-20
CN105343871A (zh) 2016-02-24
EP2419097A4 (en) 2012-09-05
DK2601949T3 (da) 2015-01-05
EP2601949A3 (en) 2013-09-18
PT2601949E (pt) 2014-11-12
PT2419097E (pt) 2013-10-03
RU2532330C2 (ru) 2014-11-10
KR20150046382A (ko) 2015-04-29
JP5077786B2 (ja) 2012-11-21
TW201622720A (zh) 2016-07-01
JP6066144B2 (ja) 2017-01-25
PH12015500235A1 (en) 2015-12-02
SG175154A1 (en) 2011-11-28
ZA201106727B (en) 2012-11-28
SG2014015093A (en) 2014-04-28
SG2014012405A (en) 2014-05-29
NZ606888A (en) 2014-07-25
SMT201500015B (it) 2015-03-05
JP2012524710A (ja) 2012-10-18
CN105343059A (zh) 2016-02-24
RU2014121260A (ru) 2015-12-10
EP2829271A3 (en) 2015-05-27
CY1115907T1 (el) 2017-01-25
SI2601949T1 (sl) 2014-12-31
JP2015063543A (ja) 2015-04-09
CA2755392A1 (en) 2010-10-21
JP5910711B2 (ja) 2016-04-27
EP2601949B1 (en) 2014-10-29
UA111742C2 (uk) 2016-06-10
CN105477639A (zh) 2016-04-13
NZ595314A (en) 2013-03-28
EP2419097B1 (en) 2013-09-25
HK1217435A1 (zh) 2017-01-13
MX2011010901A (es) 2011-11-01
HK1217302A1 (zh) 2017-01-06
CN102395364A (zh) 2012-03-28
ES2431300T3 (es) 2013-11-25
CN105343880A (zh) 2016-02-24
MY183793A (en) 2021-03-16
AU2010237748A1 (en) 2011-10-20
PH12019500959B1 (en) 2020-06-29
JP2013006854A (ja) 2013-01-10
PL2419097T3 (pl) 2014-02-28
HK1218871A1 (zh) 2017-03-17
PH12019500961B1 (en) 2020-08-03
BRPI1012539A2 (pt) 2016-03-29
US20120040898A1 (en) 2012-02-16
CN105434430A (zh) 2016-03-30
CN105343060A (zh) 2016-02-24
TW201500043A (zh) 2015-01-01

Similar Documents

Publication Publication Date Title
RS53761B1 (sr) Farmaceutski preparati sa (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom insulina
ES2302702T3 (es) Composicion farmaceutica que comprende una combinacion de metformina y glibenclamida.
TW201040193A (en) Pharmaceutical composition, methods for treating and uses thereof
CN103402506A (zh) 用于治疗糖尿病的组合
Basile A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition
TWI725317B (zh) 新穿心蓮內酯之組成物用於血糖調降之應用
WO2022089133A1 (zh) 一种降低血糖的组合、应用和方法
JP2021520403A (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
Aye et al. First-line drug management
HK1165292A (en) Pharmaceutical compositions
AU2014221222A1 (en) Pharmaceutical compositions